May 2025 in “Actas Dermo-Sifiliográficas” Botulinum toxin is not effective for treating androgenetic alopecia.
Avicennia marina extract and avicequinone C can potentially promote hair growth and treat hair loss by interfering with hair loss mechanisms and boosting growth factors.
54 citations
,
July 2002 in “Clinical and Experimental Dermatology” DHT, a testosterone byproduct, causes male pattern baldness.
April 2026 in “Zenodo (CERN European Organization for Nuclear Research)” Nanocarriers could improve minoxidil delivery for better hair loss treatment.
September 2022 in “Zenodo (CERN European Organization for Nuclear Research)” 9 citations
,
February 2004 in “Veterinary Dermatology” Canine hair follicle cells metabolize DHEA and testosterone differently than human cells.
4 citations
,
January 2002 in “Annals of Dermatology” Androgenetic alopecia, or hair loss, is most common in people in their 30s, can start early, is often inherited, and may be influenced by factors like hormones and scalp health.
April 2025 in “International Journal of Dermatology and Venereology” Androgenetic alopecia may cause schizophrenia, but schizophrenia does not cause androgenetic alopecia.
June 2026 in “JAAD reviews.” 38 citations
,
October 2005 in “Expert opinion on therapeutic patents” Selective androgen receptor modulators (SARMs) are a promising type of drug for various health conditions due to their targeted actions.
January 2024 in “Brazilian Journal of Hair Health” Androgens might not be the only major factor in hair loss; other elements could also be important.
January 2020 in “Medical journal of Dr. D.Y. Patil Vidyapeeth” Indian women with skin signs of high male hormones often have related health issues.
1 citations
,
March 2000 in “PubMed” A 16-year-old boy's alopecia areata progressed unusually to resemble male pattern baldness.
10 citations
,
March 2019 in “Journal of neuroendocrinology” Testosterone affects stress hormone levels differently in adolescent and adult male rats.
The treatment showed promising results in improving advanced-stage hair loss.
1 citations
,
January 1995 in “Journal of Investigative Dermatology” RU58841, a substance from France, can potentially block the effects of hormones that cause hair loss and excessive hair growth, performing better than a similar substance, cyproterone acetate.
14 citations
,
September 2007 in “Steroids” The study concluded that androstendione and DHEA are important for diagnosing high male hormone levels in women with excessive hair growth.
Dark hair with a red beard likely evolved for camouflage, not attraction.
January 2022 in “International Journal of Pharmacognosy and Pharmaceutical Sciences” Semecarpus anacardium Linn. has multiple medicinal benefits, including anti-inflammatory and antioxidant effects.
18 citations
,
February 2016 in “The Journal of Clinical Endocrinology and Metabolism” Advancements in male reproductive medicine are ongoing, but more research and improved treatments are needed in several areas.
2 citations
,
February 2003 in “Obstetrical & Gynecological Survey” Most antiandrogen treatments effectively reduce acne in hyperandrogenic women, but finasteride is the least effective.
April 2024 in “Dermatology reports” Dutasteride is more effective than finasteride for hair regrowth in male and female pattern hair loss, with similar side effects.
1 citations
,
February 2013 in “Steroids” Bone mineral and minocycline boost bone cell growth, aiding healing.
Finasteride impairs sperm quality and fertility in rats, even after stopping treatment.
2 citations
,
January 2018 in “Journal of The European Academy of Dermatology and Venereology” Almost 40% of Greek women with acne show signs of androgen-related disorders, with adult women more likely affected.
299 citations
,
March 2001 in “Journal of Investigative Dermatology” Male pattern baldness is linked to specific genetic variations in the androgen receptor gene.
5 citations
,
January 2017 in “Biomedical Research-tokyo” Long-term steroid abuse in athletes causes serious health risks, outweighing any benefits.
3 citations
,
January 1992 in “Gynecological Endocrinology” 3α, 17β-androstanediol-glucuronide is not a useful marker for androgen excess but may help monitor certain treatments.